Pfizer (PFE) Q3 2024 Earnings
PFE·Reported October 29, 2024·Before market open
Pfizer reported Q3 2024 revenue of $17.7B, beat analyst consensus of $14.9B by $2.8B. Diluted EPS came in at $1.06, beat the $0.61 consensus by $0.45. Pfizer reports across 2 business segments, led by Biopharmaceutical Products and Biosimilars.
Revenue
$17.7Bbeat by $2.8B
Consensus: $14.9BDiluted EPS
$1.06beat by $0.45
Consensus: $0.61
Financial Snapshot
Trailing eight quarters through Q3 2024
Q3 2024 Earnings FAQ
Common questions about Pfizer's Q3 2024 earnings report.
Pfizer (PFE) reported Q3 2024 earnings on October 29, 2024 before market open.
Pfizer reported revenue of $17.7B and diluted EPS of $1.06 for Q3 2024.
Revenue beat the consensus estimate of $14.9B by $2.8B. EPS beat the consensus estimate of $0.61 by $0.45.
You can read the 10-Q periodic report (0000078003-24-000191) directly on SEC EDGAR. The filing index links above go to sec.gov.